Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure

This publication has 12 references indexed in Scilit:

• A Randomized Clinical Trial Evaluating Sequential Methotrexate and Fluorouracil in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor-Negative Tumors
  New England Journal of Medicine, 1989
• EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTORS ASSOCIATED WITH LACK OF RESPONSE TO ENDOCRINE THERAPY IN RECURRENT BREAST CANCER
  The Lancet, 1989
• Quantitative assays of epidermal growth factor receptor in human breast cancer: Cut‐off points of clinical relevance
  International Journal of Cancer, 1988
• Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06.
  Journal of Clinical Oncology, 1988
• Five-Year Results of a Randomized Clinical Trial Comparing Total Mastectomy and Segmental Mastectomy with or without Radiation in the Treatment of Breast Cancer
  New England Journal of Medicine, 1985
• EPIDERMAL-GROWTH-FACTOR RECEPTORS AND OESTROGEN RECEPTORS IN HUMAN BREAST CANCER
  The Lancet, 1985
• Epidermal growth factor receptors in human breast cancer
  Breast Cancer Research and Treatment, 1984
• ŒSTROGEN RECEPTORS AND PROGNOSIS IN EARLY BREAST CANCER
  The Lancet, 1979
• Patterns of relapse and survival following radical mastectomy.Analysis of 716 consecutive patients
  Cancer, 1978
• Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
  British Journal of Cancer, 1977